Mechanistic drivers of PD-L1/CTLA-4 checkpoint inhibitor-associated immune toxicity and systemic organ injury
{{output}}
Background: Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have substantially improved outcomes in multiple malignancies, but they may also trigger dysregulated immune activation accompanied by systemic toxic effect... ...
